Agenus (NASDAQ:AGEN) Announces Quarterly Earnings Results

Agenus (NASDAQ:AGEN) released its earnings results on Thursday. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19), Zacks reports. The business had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same quarter last year, the firm posted ($4.00) earnings per share.

Agenus Stock Down 3.6 %

AGEN traded down $0.19 during trading on Friday, reaching $5.09. 265,879 shares of the company’s stock were exchanged, compared to its average volume of 744,298. Agenus has a fifty-two week low of $4.78 and a fifty-two week high of $32.00. The business has a 50 day moving average price of $12.34 and a 200 day moving average price of $12.04. The company has a market capitalization of $106.88 million, a P/E ratio of -0.40 and a beta of 1.33.

Analysts Set New Price Targets

AGEN has been the subject of several research reports. StockNews.com initiated coverage on shares of Agenus in a research report on Wednesday, April 17th. They set a “hold” rating for the company. William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. HC Wainwright cut shares of Agenus from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $40.00 to $9.00 in a report on Thursday, July 18th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $8.00 in a report on Friday, July 19th. Finally, Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $31.00.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.